Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $421.80, for a total value of $9,490,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Michael Benkowitz also recently made the following trade(s):

• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $416.35, for a total value of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $400.56, for a total value of $9,012,600.00.
• On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The shares were sold at an average price of $392.21, for a total transaction of $1,961,050.00.
• On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The shares were sold at an average price of $397.41, for a total transaction of $4,520,538.75.
• On Tuesday, September 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $443.44 on Friday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $444.57. The firm has a market capitalization of $20.00 billion, a P/E ratio of 17.31, a P/E/G ratio of 6.68 and a beta of 0.66. The company’s 50 day simple moving average is $353.34 and its 200 day simple moving average is $318.06.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter in the previous year, the firm posted $5.85 EPS. The business’s revenue was up 11.7% on a year-over-year basis. Sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on UTHR shares. Bank of America boosted their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Jefferies Financial Group lifted their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research note on Tuesday, July 8th. Oppenheimer increased their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Finally, Morgan Stanley decreased their price target on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a report on Thursday, July 10th. Ten investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $449.57.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. F m Investments LLC boosted its position in United Therapeutics by 1.3% during the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 33 shares during the last quarter. HB Wealth Management LLC raised its holdings in shares of United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares during the last quarter. Hohimer Wealth Management LLC lifted its position in shares of United Therapeutics by 0.3% in the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock worth $3,900,000 after purchasing an additional 37 shares in the last quarter. WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its holdings in United Therapeutics by 1.7% during the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 39 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.